The contribution of the polymorphism of MMR 12 (rs652483) and PPARG (rs1801282) genes to the formation of NAFLD in obese patients

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The increase in the incidence of non-alcoholic fatty liver disease (NAFLD) among people of working age is due to the large influence of environmental factors, while the role of the genetic aspect in the formation and progression of this disease is debatable. The purpose. To study the frequency of occurrence of allele pairs by polymorphic loci of matrix metalloproteinase MMP12 (rs652483) genes and gamma receptor activated by peroxisome proliferator PPARG (rs1801282) and to determine the role of genes in the formation of NAFLD in obese women and compare with practically healthy women in Perm. Material and methods. The study included 100 obese patients who were divided into groups: group 1 (n=50) patients without NAFLD (average age 43,3±5,6 years); group 2 (n=50) patients with established NAFLD (average age 45,3±3,2 years). The control group consisted of 100 healthy women from Perm. Single nucleotide polymorphic variants of genes were determined by the method of allele-specific polymerase chain reaction using sets of genes MMP12 (rs 652483), PPARG (rs1801282). Results. Carrying the Pro12Pro genotype of the PPARG gene increases the risk of obesity by 2 times (x2=5,31, p=0,02, OR 2,05), carrying the Pro12Ala genotype reduced the risk of obesity and NAFLD by 1,7 times (x2=5,89, p=0,04, OR 0,58). Carrying the pPArG genotype Pro12Pro increases the risk of developing NAFLD in obese patients by 2,5 times. Carrying the polymorphism of the Ala12Ala genotype reduced the risk of obesity by 9 times (x2=4,23; p=0,04; OR 0,11). Carriers of the Ala12Ala genotype were associated with an increase in IGF-1 levels (p=0,024), carriers of the Pro12Pro genotype with an increase in TG levels (p=0,018). The associations of the carrier of the polymorphic position of the MMR12 gene with an increase in the waist/hip ratio (p=0,02), cystatin C (p=0,01) and MCP-1 (p=0,004) were obtained. Conclusions. In the female population carrying the PPARG gene polymorphism (rs1801282) of the Ala12Al genotype reduces the risk of obesity and metabolic disorders, carrying the Pro12 Pro genotype increases the risk of obesity and NAFLD. The carrier of the polymorphism of the MMR 12 gene (rs 652438) in women is associated with the development of abdominal obesity and systemic inflammatory response.

全文:

受限制的访问

作者简介

Sofia Shulkina

Academician E.A. Wagner Perm State Medical University of the Ministry of Healthcare of Russia

Email: shulkina-s@mail.ru
Dr. med. habil., professor of the Department of polyclinic therapy

Polina Erbes

Academician E.A. Wagner Perm State Medical University of the Ministry of Healthcare of Russia

Email: erbespolin@gmail.com
assistant at the Department of polyclinic therapy

Elena Smirnov

Academician E.A. Wagner Perm State Medical University of the Ministry of Healthcare of Russia

Dr. med. habil., professor, head of the Department of endocrinology and clinical pharmacology

参考

  1. Grunvald E., Shah R., Hernaez R. et al.; AGA Clinical Guidelines Committee. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022; 163(5): 1198-225. https://dx.doi.org/10.1053Zj.gastro.2022.08.045.
  2. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016, 64(6): 1388-402. http://dx.doi.org/10.1016/j.jhep.2015.11.004.
  3. Yao Y.S., Li J., Jin Y.L. Association between PPAR-y2 Pro12Ala polymorphism and obesity: A meta-analysis. Mol Biol Rep. 2015; 42(6): 1029-38. https://dx.doi.org/10.1007/s11033-014-3838-6.
  4. Хасанова К.Б., Медведева М.С., Валеева Е.В. с соавт. Роль полиморфизма rs1801282 гена PPARG в прогнозировании риска развития нарушений углеводного обмена и выборе тактики лечения. Consilium Medicum. 2022; 24(4): 266-270. [Khasanova K.B., Medvedeva M.S., Valeeva E.V. et al. The role of polymorphism rs1801282 of the PPARG gene in predicting the risk of carbohydrate metabolism disorders and the choice of treatment tactics. Consilium Medicum. 2022; 24(4): 266-270 (In Russ.)]. https://dx.doi.org/10.26442/20751753.2022.4.201672. EDN: WMLANF.
  5. Москаленко М.И., Пономаренко И.В., Верзилина И.Н. с соавт. Роль ген-генных и генно-средовых взаимодействий полиморфных локусов ММР в формировании артериальной гипертензии у женщин. Артериальная гипертензия. 2020; 26(5): 518-525. [Moskalenko M.I., Ponomarenko I.V., Verzilina I.N. et al. The role of gene-gene and geneenvironment interactions of polymorphic locuses of MMPs in the formation of hypertension in women. Arterial'naya gipertenziya = Arterial Hypertension. 2020; 26(5): 518-525 (In Russ.)]. https://dx.doi.org/10.18705/1607-419X-2020-26-5-518-52. EDN: OUFVXS.
  6. Bhatt S.P., Misra A., Sharma M. et al. Ala/Ala genotype of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-Y2 gene is associated with obesity and insulin resistance in Asian Indians. Diabetes Technol Ther. 2012; 14(9) :828-34. https://dx.doi.org/10.1089/dia.2011.0277.
  7. Бондарь И.А., Филипенко М.Л., Шабельникова О.Ю., Соколова Е.А. Ассоциация полиморфного маркера RS1801282 гена PPARG PRO12ALA с сахарным диабетом 2-го типа в Новосибирской области и других популяциях. Сибирский журнал клинической и экспериментальной медицины. 2014; 29(2): 75-78. [Bondar I.A., Filipenko M.L., Shabelnikova O.Yu., Sokolova E.A. Association of polymorphic marker RS1801282 of the PPARG PRO12ALA gene with type 2 diabetes mellitus in the Novosibirsk region and other populations. Sibirskiy zhurnal klinicheskoy i eksperimental'noy meditsiny = Siberian Journal of Clinical and Experimental Medicine. 2014; 29(2): 75-78 (In Russ.)]. https://dx.doi.org/10.29001/2073-8552-2014-29-2-75-78. EDN: TWKREH.
  8. Еременко Т.В. Ассоциация полиморфизма rs1801282 с различными компонентами метаболического синдрома. Вестник СевероЗападного государственного медицинского университета имени И.И. Мечникова. 2018; 10(3): 60-64. [Eremenko T.V. Association of polimorphism rs1801282 with different components of the metabolic syndrome. Vestnik Severo-Zapadnogo gosudarstvennogo meditsinskogo universiteta imeni I.I. Mechnikova = Herald of North-Western State Medical University named after I.I. Mechnikov. 2018; 10(3): 60-64 (In Russ.)]. https://dx.doi.org/10.17816/mechnikov201810360-64. EDN: XUOIUP.
  9. Валеева Ф.В., Медведева М.С., Хасанова К.Б. с соавт. Изменение показателей состава тела в зависимости от полиморфизма rs1801282 гена PPARG у пациентов с различными вариантами терапии ранних нарушений углеводного обмена. Медицинский вестник Юга России. 2021; 12(4): 27-33. [Valeeva F.V., Medvedeva M.S., Khasanova K.B. et al. Changes in body composition depending on the rs1801282 PPARG polymorphism in patients with different variants of treatment of early carbohydrate metabolism disorders. Meditsinskiy vestnik Yuga Rossii = Medical Herald of the South of Russia. 2021; 12(4): 27-33 (In Russ.)]. https://dx.doi.org/10.21886/2219-8075-2021-12-4-27-33. EDN: HIXSOC.
  10. Morini E., Tassi V., Capponi D. et al. Interaction between PPARy2 variants and gender on the modulation of body weight. Obesity (Silver Spring). 2008; 16(6): 1467-70. https://dx.doi.org/10.1038/oby.2008.225.
  11. Лазебник Л.Б., Радченко В.Г., Джадхав С.Н. с соавт. Системное воспаление и неалкогольная жировая болезнь печени. Экспериментальная и клиническая гастроэнтерология. 2019; 5: 29-41. [Lazebnik L.B., Radchenko V.G., Dzhadkhav S.N. et al. Systemic infl ammation and non-alcoholic fatty liver disease. Eksperimental'naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2019; 5: 29-41 (In Russ.)]. https://dx.doi.org/10.31146/1682-8658-ecg-165-5-29-41. EDN: GORLHA.
  12. Мангилева Т.А., Гафарова Н.Х. Метаболические и гемодинамические эффекты системы гормон роста - инсулиноподобный фактор роста. Терапевтический архив. 2015; 87(12): 128-133. [Manhylova T.A., Gafarova N.H. Metabolic and hemodynamic effects of the growth hormone system - insulin-like growth factor. Terapevticheskiy arkhiv = Therapeutic Archive. 2015; 87(12): 128-133 (In Russ.)]. https://dx.doi.org/10.17116/terarkh20158712128-133. EDN: VKWGUP.
  13. Журавлева Л.В., Огнева Е.В. Инсулиноподобный фактор роста-1, цитолиз и холестаз у больных неалкогольной жировой болезнью печени и при ее сочетании с сахарным диабетом 2-го типа. Клиницист. 2013; 7(3-4): 48-52. [Zhuravlyova L.V., Ogneva E.V. Insulin-like growth factor-1, cytolysis and choltstasis in patients with non-alcoholic fatty liver disease and its combination with type 2 diabetes mellitus. Klinitsist = The Clinician. 2013; 7(3-4): 48-52 (In Russ.)]. EDN: SHUGPX.
  14. Пивоваров А.В. Взаимосвязь инсулиноподобного фактора роста-1 и показателей углеводного обмена у больных с артериальной гипертензией и сахарным диабетом 2 типа. Научный результат. Медицина и фармация. 2017; 3(1): 8-14. [Pivovarov A.V. Relationship between insulin-like growth factor-1 and parameters of carbohydrate metabolism in patients with arterial hypertension and type 2 diabetes mellitus. Nauchnyy rezul'tat. Meditsina i farmatsiya = Research Result. Medicine and Pharmacy. 2017; 3(1): 8-14 (In Russ.)]. https://dx.doi.org/10.18413/2313-8955-2017-3-1-8-14. EDN: VRJANO.
  15. Wang L., Ma Y.T., Xie X. et al. Interaction between MMP 9 gene polymorphisms and smoking in relation to myocardial infarction in a Uighur population. Clin Appl Thromb Hemost. 2012; 18(1): 72-78. https://dx.doi.org/10.1177/1076029611412365.
  16. Andrade V.L., Petruceli E., Belo V.A. et al. Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women. Clin Biochem. 2012; 45(6): 412-15. https://dx.doi.org/10.1016/j.clinbiochem.2012.01.008.
  17. Fiotti N., Calvagna C., Sgorlon G. et al. Multiple sites of vascular dilation or aneurysmal disease and matrix metalloproteinase genetic variants in patients with abdominal aortic aneurysm. J. Vasc Surg. 2018; 67(6): 1727-35. https://dx.doi.org/10.1016/j.jvs.2017.09.047.
  18. Zhang G., Li W., Guo Y. et al. MMP gene polymorphisms, MMP 1-1607 1G/2G,-519 A/G., and MMP 12-82 A/G., and ischemic stroke: A meta-analysis. J. Stroke Cerebrovasc Dis. 2018; 27(1): 140-52. https://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2017.08.021.
  19. Колотов К.А., Распутин П.Г. Моноцитарный хемотаксический протеин-1 в физиологии и медицине. Пермский медицинский журнал. 2018; 35(3): 99-105. [Kolotov K.A., Rasputin P.G. Monocytic chemotactic protein-1 in physiology and medicine (review of literature). Permskiy meditsinskiy zhurnal = Perm Medical Journal. 2018; 35(3): 99-105 (In Russ)]. https://dx.doi.org/10.17816/pmj35399-105. EDN: XSBYEX.
  20. Шулькина С.Г., Смирнова Е.Н. Диагностическое значение цистатина С. и коллагена IV типа у больных артериальной гипертензией и ожирением. Артериальная гипертензия. 2017; 23(6): 552-560. [Shulkina S.G., Smirnova E.N. Diagnostic value of cystatin C. and collagen type IV in patients with hypertension and obesity. Arterial'naya gipertenziya = Arterial Hypertension. 2017; 23(6): 552-560 (In Russ.)]. https://dx.doi.org/10.18705/1607-419X-2017-23-6-552-560. EDN: RQGBGL.
  21. Юзько Ю.В. Изменения различных классов протеаз и ингибиторов протеаз как возможных сывороточных маркеров фиброза у больных хроническим гепатитом С: Автореф. дисс. канд. мед. наук. Новосибирск. 2007.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2022
##common.cookie##